PortfoliosLab logoPortfoliosLab logo
LEA vs. IONS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LEA vs. IONS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lear Corporation (LEA) and Ionis Pharmaceuticals, Inc. (IONS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, LEA achieves a 15.32% return, which is significantly higher than IONS's -34.56% return. Over the past 10 years, LEA has outperformed IONS with an annualized return of 3.77%, while IONS has yielded a comparatively lower 3.21% annualized return.


LEA

1D
-10.72%
1M
-0.16%
6M
12.87%
YTD
15.32%
1Y
44.05%
3Y*
-2.88%
5Y*
-3.38%
10Y*
3.77%
ALL TIME*
11.98%

IONS

1D
-2.83%
1M
-36.71%
6M
-37.38%
YTD
-34.56%
1Y
20.31%
3Y*
7.90%
5Y*
6.87%
10Y*
3.21%
ALL TIME*
5.06%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$189.49M$272.86M$184.93M
$107.51M$84.47M$90.13M

LEA vs. IONS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
LEA
Lear Corporation
15.32%24.86%-31.17%16.40%-30.70%16.20%16.90%14.38%-29.29%35.23%
IONS
Ionis Pharmaceuticals, Inc.
-34.56%126.29%-30.90%33.94%24.12%-46.18%-6.41%11.75%7.48%5.16%

Correlation

The correlation between LEA and IONS is 0.17, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.17

Correlation (3Y)
Balances recent behavior with more history.

0.24

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.25

Correlation (10Y)
Provides a long-term view across more market conditions.

0.22

Correlation (All Time)
Calculated using the full available price history since Nov 9, 2009

0.26

Fundamentals

Market Cap

LEA:

$6.54B

IONS:

$8.60B

EPS

LEA:

$10.65

IONS:

-$3.46

PS Ratio

LEA:

0.29

IONS:

9.67

PB Ratio

LEA:

0.75

IONS:

19.47

Total Revenue (TTM)

LEA:

$23.70B

IONS:

$873.76M

Gross Profit (TTM)

LEA:

$789.80M

IONS:

$857.70M

EBITDA (TTM)

LEA:

$1.18B

IONS:

$4.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LEA vs. IONS — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

LEA
LEA Risk / Return Rank: 8080
Overall Rank
LEA Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
LEA Sortino Ratio Rank: 7979
Sortino Ratio Rank
LEA Omega Ratio Rank: 7777
Omega Ratio Rank
LEA Calmar Ratio Rank: 8181
Calmar Ratio Rank
LEA Martin Ratio Rank: 8181
Martin Ratio Rank

IONS
IONS Risk / Return Rank: 6060
Overall Rank
IONS Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
IONS Sortino Ratio Rank: 5858
Sortino Ratio Rank
IONS Omega Ratio Rank: 6464
Omega Ratio Rank
IONS Calmar Ratio Rank: 5858
Calmar Ratio Rank
IONS Martin Ratio Rank: 6262
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

LEA vs. IONS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lear Corporation (LEA) and Ionis Pharmaceuticals, Inc. (IONS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


LEAIONSDifference
Sharpe ratioReturn per unit of total volatility

+0.89

Sortino ratioReturn per unit of downside risk

+0.98

Omega ratioGain probability vs. loss probability

1.24

1.16

+0.08

Calmar ratioReturn relative to maximum drawdown

2.23

0.51

+1.72

Martin ratioReturn relative to average drawdown

5.54

1.64

+3.90

LEA vs. IONS - Sharpe Ratio Comparison

The current LEA Sharpe Ratio is 1.27, which is higher than the IONS Sharpe Ratio of 0.39. The chart below compares the historical Sharpe Ratios of LEA and IONS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

LEA vs. IONS - Drawdown Comparison

The maximum LEA drawdown since its inception was -64.51%, smaller than the maximum IONS drawdown of -91.42%. Use the drawdown chart below to compare losses from any high point for LEA and IONS.


Loading charts...

Drawdown Indicators


LEAIONSDifference

Max Drawdown

Largest peak-to-trough decline

-64.51%

-91.42%

+26.91%

Max Drawdown (1Y)

Largest decline over 1 year

-18.98%

-40.15%

+21.17%

Max Drawdown (3Y)

Largest decline over 3 years

-49.42%

-52.36%

+2.94%

Max Drawdown (5Y)

Largest decline over 5 years

-57.83%

-52.36%

-5.47%

Max Drawdown (10Y)

Largest decline over 10 years

-64.51%

-70.39%

+5.88%

Current Drawdown

Current decline from peak

-27.38%

-40.15%

+12.77%

Average Drawdown

Average peak-to-trough decline

-19.85%

-52.26%

+32.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.64%

12.53%

-4.89%

Volatility

LEA vs. IONS - Volatility Comparison

The current volatility for Lear Corporation (LEA) is 13.77%, while Ionis Pharmaceuticals, Inc. (IONS) has a volatility of 29.82%. This indicates that LEA experiences smaller price fluctuations and is considered to be less risky than IONS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LEAIONSDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.77%

29.82%

-16.05%

Volatility (6M)

Calculated over the trailing 6-month period

27.11%

35.47%

-8.36%

Volatility (1Y)

Calculated over the trailing 1-year period

33.24%

52.79%

-19.55%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

34.34%

43.75%

-9.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

35.39%

45.64%

-10.25%

Dividends

LEA vs. IONS - Dividend Comparison

LEA's dividend yield for the trailing twelve months is around 2.36%, while IONS has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
IONS
Ionis Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LEA
Lear Corporation
2.36%2.69%3.25%2.18%2.48%0.97%0.64%2.19%2.28%1.13%0.91%0.81%

Financials

LEA vs. IONS - Financials Comparison

This section allows you to compare key financial metrics between Lear Corporation and Ionis Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

LEA vs. IONS - Profitability Comparison

The chart below illustrates the profitability comparison between Lear Corporation and Ionis Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

LEA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Lear Corporation reported a gross profit of -442.10M and revenue of 6.21B. Therefore, the gross margin over that period was -7.1%.

IONS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported a gross profit of 265.21M and revenue of 267.95M. Therefore, the gross margin over that period was 99.0%.

LEA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Lear Corporation reported an operating income of -259.80M and revenue of 6.21B, resulting in an operating margin of -4.2%.

IONS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported an operating income of -102.29M and revenue of 267.95M, resulting in an operating margin of -38.2%.

LEA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Lear Corporation reported a net income of 192.80M and revenue of 6.21B, resulting in a net margin of 3.1%.

IONS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported a net income of -114.65M and revenue of 267.95M, resulting in a net margin of -42.8%.


Frequently Asked Questions


LEA and IONS have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IONS has higher volatility (29.82%) compared to LEA (13.77%). In terms of maximum drawdown, LEA dropped -64.51% vs IONS's -91.42%.

LEA currently has the higher Sharpe Ratio (1.27 vs 0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LEA and IONS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer